Ribavirin quantification in combination treatment of chronic hepatitis C

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 124-129

  Larrat, Sylvie ^a   Stanke Labesque, Françoise ^a,b   Plages, Agnès ^a   Zarski, Jean Pierre ^a   Bessard, Germain ^a   Souvignet, Claude ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; NUCLEOSIDE ANALOG; RIBAVIRIN;

ACCURACY; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; TREATMENT FAILURE;

ADULT; AGED; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 0037226397     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.124-129.2003     Document Type: Article

References (20)

1. Austin, R. K., P. E. Trefts, M. Hintz, J. D. Connor, and M. F. Kagnoff. 1983. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob. Agents Chemother. 24:696-701.
2. Braconier, J. H., O. Paulsen, K. Engman, and A. Widell. 1995. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand. J. Infect. Dis. 27:325-329.
3. Davis, G. L. 1999. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Semin. Liver Dis. 19:49-55.
4. Glue, P. 1999. The clinical pharmacology of ribavirin. Semin. Liver Dis. 19:17-24.
5. Granich, G. G., D. J. Krogstad, J. D. Connor, K. L. Desrochers, and C. Sherwood. 1989. High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay. Antimicrob. Agents Chemother. 33:311-315.
6. Heathcote, J. 2000. Antiviral therapy for patients with chronic hepatitis C. Semin. Liver Dis. 20:185-199.
7. Homma, M., A. L. Jayewardene, J. Gambertoglio, and F. Aweeka. 1999. High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes. Antimicrob. Agents Chemother. 43:2716-2719.
8. Jen, J. F., P. Glue, S. Gupta, D. Zambas, and G. Hajian. 2000. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther. Drug Monit. 22:555-565.
9. Khakoo, S., P. Glue, L. Grellier, B. Wells, A. Bell, C. Dash, I. Murray-Lyon, D. Lypnyj, B. Flannery, K. Walters, and G. M. Dusheiko. 1998. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br. J. Clin. Pharmacol. 46:563- 570.
10. Lafeuillade, A., G. Hittinger, and S. Chadapaud. 2001. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357:280-281.
11. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
12. McHutchison, J. G., and T. Poynard, 1999. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin. Liver Dis. 19:57-65.
13. Paroni, R., C. R. Sirtori, C. Borghi, and M. G. Kienle. 1987. High-performance liquid chromatographic determination of ribavirin in serum and urine and of its urinary metabolite 1,2,4-triazole-3-carboxamide. J. Chromatogr. 420:189-196.
14. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, J. Albrecht, et al. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
15. Preston, S. L., G. L. Drusano, P. Glue, J. Nash, S. K. Gupta, and P. McNamara. 1999. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob. Agents Chemother. 43:2451-2456.
16. Roboz, J., and R. Suzuki. 1978. Determination of 1-beta-D-ribofuranosyl1,2,4-triazole-3-carboxamide (virazole) in blood and urine by chemical ionization-mass fragmentography. J. Chromatogr. 160:169-179.
17. Shah, V. P., K. K. Midha, S. Dighe, I. J. McGilveray, J. P. Skelly, A. Yacobi, T. Layloff, C. T. Viswanathan, C. E. Cook, R. D. McDowall, et al. 1991. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur. J. Drug Metab. Pharmacokinet. 16:249-255.
18. Shah, V. P., K. K. Midha, J. W. Findlay, H. M. Hill, J. D. Hulse, I. J. McGilveray, G. McKay, K. J. Miller, R. N. Patnaik, M. L. Powell, A. Tonelli, C. T. Viswanathan, and A. Yacobi. 2000. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17:1551-1557.
19. Smith, R. H., and B. E. Gilbert. 1987. Quantification of ribavirin in biological fluids and tissues by high-performance liquid chromatography. J. Chromatogr. 414:202-210.
20. Svensson, J. O., A. Bruchfeld, R. Schvarcz, and L. Stahle. 2000. Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography. Ther. Drug Monit. 22:215-218.